Nebicapone
Nebicapone[edit | edit source]
Nebicapone is a pharmaceutical compound that functions as a catechol-O-methyltransferase (COMT) inhibitor. It is primarily investigated for its potential use in the treatment of Parkinson's disease, a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the brain.
Mechanism of Action[edit | edit source]
Nebicapone works by inhibiting the enzyme catechol-O-methyltransferase (COMT). COMT is responsible for the breakdown of catecholamines, including dopamine, which is a critical neurotransmitter involved in motor control. By inhibiting COMT, nebicapone increases the availability of dopamine in the brain, thereby helping to alleviate the motor symptoms associated with Parkinson's disease.
Pharmacokinetics[edit | edit source]
Nebicapone is administered orally and is absorbed through the gastrointestinal tract. It undergoes hepatic metabolism and is excreted primarily via the renal route. The pharmacokinetic profile of nebicapone includes a half-life that supports its use in a once-daily dosing regimen, which can improve patient compliance.
Clinical Trials[edit | edit source]
Clinical trials have been conducted to evaluate the efficacy and safety of nebicapone in patients with Parkinson's disease. These studies have shown that nebicapone, when used as an adjunct to levodopa therapy, can reduce "off" time and improve "on" time without dyskinesia, which are common challenges in the management of Parkinson's disease.
Side Effects[edit | edit source]
The side effects of nebicapone are generally mild to moderate and may include nausea, dizziness, and headache. As with other COMT inhibitors, there is a potential risk of liver toxicity, and liver function tests are recommended during treatment.
Regulatory Status[edit | edit source]
As of the latest updates, nebicapone is not yet approved for widespread clinical use and remains under investigation in various clinical trials. Its approval status may vary by country and is subject to the outcomes of ongoing research.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
